MYGN - Earnings call transcript Q4 2018

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standby. Welcome to the Myriad Genetics Fourth Quarter 2018 Financial Earnings Conference Call.

During the presentation all participants will be in a listen-only mode. Afterwards, we will conduct a question-and-answer session. [Operator Instructions] As a reminder, this conference is being recorded, Tuesday, August 21, 2018. to Investor conference Relations. like Gleason, to now President, Vice would turn over the Scott I Please ahead. go

Scott Gleason

Thanks, Mike. name Good Investor Genetics I fiscal afternoon. the Relations. And welcome quarter am earnings to XXXX call. President My Vice is Gleason. fourth Scott of the Myriad

which During after will released we a host call, the financial will the we question-and-answer results review today, we session.

Financial Chief via myriad.com. Executive Officer; a Officer. call in will Presenting and This earnings release, our myriad.com. Investors at be in can Bryan found the is If live be website. Relations Riggsbee, President the website Myriad section heard Mark archived recorded you it and our and from review at Chief have today be be will chance to The not being call of Investor had webcast the section Capone, of can

presentation and statements. call return the to Exchange differ pleased Quarterly specifically am could documents XX-Q that files risk X-K. With its in a time and our results from Form the or or that, documents today’s its In Commission, regarding with today on the materially Annual call the Form be slide materially our to Securities company on refer reports these for the call events there current and will forward-looking of some and actual may of which pertaining addition, of you These section contain and the I website information the on Please that We contained to presented note financial on the X-K. performance Form These on Investors following variety is important statements earnings are Mark. future a management’s reasons. the to factors time identify expectations Report events the from and Reports to forward-looking based those may results adversely other differ the projections or actual statements of from to projections current cause company. expectations future XX-K, company’s on filed

Mark Capone

by by providing call I quarter, Thanks, Scott. provide the would fiscal providing our inflection an $XXX.X adjusted of fiscal for and after trends in to like finish In and on current and details fourth Riggsbee revenues and regarding quarter, again results highlights year key of our will I Bryan with initiatives then the will information per additional drive exceeded which earnings today’s call start our financial $X.XX. guidance, to in our fourth the share we once XXXX. expectations million business

of our per revenue million which recent share and For our significantly most guidance. earnings in what line $X.XX, the reported year, and adjusted with full revised of $XXX exceeded we initial guidance is

XX% fiscal highlights the increased which structure. slight to a success reengineer For efforts our revenue, year, cost our increase the of on earnings by in

metastatic approval in in began the is the breast study, cancer pharmacogenomics culminated science in EPIC fourth riskScore values in our fundamental we U.S. of received fiscal study of pioneered field another risks. our of Japan. field This largest cancer understanding one XXXX to ago, commitment committed company, years we hereditary of patients a BRACAnalysis cancer achievement. major that pioneering commitment Having the prospective we for year GUIDED research which CDx significant completed the represented September, companion future As testing cancer the and ever and which and the a than to the health. is XX more successfully testing. in will launch neuroscience, conducted In diagnostics In of mental remain enhance hereditary scientific for

at PARP bring better that activity. demonstrating rheumatoid the of inhibitors extremely compared In three of and in measures a We best predicting pharmaceuticals broader arthritis radiographic rheumatoid pleased arthritis, Vectra have patients XX of more disease progression we committed how help class completed are group of research to patients. years to landmark select research DA to than to of to this times understand field we for patients was historical

measure manuscripts, treatment guide had total, represent and RA company In substantial For the the objective for can time, presentations a first physicians XX completely which of progress. scientific patients. and XX to use body scientific reliable published a

made cancer since It interesting XXXX, tests. new diversification products change GeneSight also note Vectra important XXXX, We and the approximately Prolaris total $XXX also hereditary when XX% to record fiscal new up fiscal of up EndoPredict a our have of with progress new Court significant with represented DA product representing XX%. than volume year in X% products In had from revenue is efforts is our the test of also XXXX XX%, sample samples. XX%, that XXX,XXX of less growing fiscal significantly we decision. million, volumes before XX% grown Supreme growing This

new important revenue a saw sequential less in severe strong to factors as volume X% revenue During riskScore a increases with success Preventive build volume the hereditary product up competitive stable growth sixth of expand represents critical sequential saw third we the we patients fourth progress market Elevate This program. strength trends quarter X% differentiator the market proven double-digit to quarter, perspective, be product cancer XXXX year-over-year result, in international kit sequentially. pricing. increase to continue new and we with and of profitability with and Care reimbursement, a From a has cancer our continued family the five histories. RNA for volume, quarter the make on grow volume foundation, upon hereditary up improve our growth solid strategically with and

and U.S. we of breast increase increased in approvals physician our and education efforts Following the in XX% tested and quarter fourth metastatic patient continue the year, sequentially the the BRACAnalysis to half patients cancer in CDx Japan. second the

population. to for These number year of more cancer indications per the changes and has endometrial the the Lastly, changes testing physicians aggregate completed the in doubled we to cancer growth we ordering in frequency since over testing XXX,XXX guidelines consistent. pancreatic, positive prostate, remaining ordering hereditary include with addressable saw contributor the relatively in GeneSight new colon than year. of significant a number significant quarter and most acquisition guidelines product major fiscal was this add the that patients expansions expanded the and

This quarter, records and strong year two XX,XXX ordering ordering with X,XXX GeneSight believe attribute both greater fiscal to study. results these new doctors new test we strength that into the physicians, we almost We XXXX. metrics than a are GUIDED set indicators heading the of

DA Prolaris approach achieved rate million also and rate $XX We saw the a fourth Vectra in $XX run million at run quarter.

business regard. units we This measure of to joining and product at quarter, We reimbursement. progress made the establishing in fiscal in strong due results, our broader reached percent addressable these our fact, units significant urology that according profitability to year, has billion the X% XX%, autoimmune reimbursement. that health, the Melanoma fourth this neuroscience business oncology and new and In Using we myPath DA both in addressable GeneSight reimbursement new women’s a at In of the XX%, market for Vectra targeted ended with year. year decision. XX%, potential per U.S. revenue at metric, products total, Prolaris exceeds at coverage $X.X X% EndoPredict at market reimbursed

With active a demonstrate the our XXth largest data, response first study, and landmark which remission versus drug upon commercial we the secured this biomarker-based intermediate it an in payer completed fiscal for coverage XX Medicare arm. low-risk covered of employer in approximately to patients. prognostic decisions we has in of technology pharmacogenomics commercially the We the payer securing new strength to published in directly testing, and resulted which year United States. making coverage eight they position we coverage significant whose standard in also or Based developed in States. the XXXX. policy care IMPACT self-funded in coverage insured statistically fiscal with have Prolaris XX% For lives CareFirst, first GUIDED significant changes the represents and by to rates GeneSight, decision of of lives studies XX% strong lives for endorsed covered saw a included went Prolaris, with Optum lives over favorable we approach groups, commercial expanded expansions recently and United was year into approximately review. million broadly in the August guidelines, the X NCCN which effect over the with up studies of put patients make are and later This us all commercial decisions study total When will favorable all published, working country additional the in coverage three updated in Xst. receive intermediate million throughout stages This XXXX. GUIDED are encompassing

the covers employees expanded GeneSight. full with as personalized the Kroger, from success agreement benefits advanced to a well. Plans, agreements DA groups Vectra best finalizing for employer contract employer Kroger in utility are a to Furthermore, who we will that for medical United approximately large the Kroger has the fourth to XX,XXX cover employer value which benefit manager a was Our with and largest medicine an GeneSight first with we Prescription second employees, cover pharmacy the diagnostics. see signed positioned that demonstrate offers self-insured are our recently These States.

reduce for adding new more payer Vectra We which to is prior also regional includes mandating received example requirement breast from With can patient total improving coverage January EndoPredict, cancer Medicare for also over XX% while tests outcomes. costs, patients. received prior DA Vectra one DA, decision a final a proprietary a of coverage This yet in LCD our to how we authorization biologic testing therapy. demonstrating increasing our

even guidelines and greater critical XXXX we fiscal for a increase fiscal reimbursement. a from momentum represent opportunity in the new data, Given transformational XXXX with believe

Moving advancing profitability restructuring announcement significant program. strategy to we year in our of and XXXX fiscal our on with international the kit-based made progress improving our business,

of We which in recently Kingdom, coverage reimbursement a year. province NICE have United currently approximately patients XX,XXX represents France, cover in we EndoPredict, to Canada. Switzerland market received Ontario, the per the and For a in EndoPredict recommendation

for Italy breast the end by year. laboratory. started the CDx BRACAnalysis evaluating Labor, testing and by Germany fiscal from in U.S. approval This Japanese of should receiving processed potential patients are which Welfare both year. regulatory Health samples, decisions fourth XX,XXX the of are and addition, the upcoming represents our and quarter, make we coverage received per In and In June for approximately Japanese market Ministry prognostic

hereditary international Munich to our our testing restructuring initiated diagnostics Lake Salt plans laboratory for facilities closed we companion Additionally, laboratory. City the and in with cancer and consolidate

have clinic of laboratory this interested identified transition have expect -- to the the the and in the We Also, by clinic XXXX. German sale calendar first we complete of have year. fiscal end initiated we of half parties the year to purchase assumed be the

return XXXX Overall, XXXX visibility stable hereditary and operating make point XXXX, and for the solidifying again process laboratory cancer $X test fiscal approximately company basis was volume the created revenue with for we in expenses improvements, made the fourth synergies. we look made Counsyl meaningful in to new a on restructuring to of growth. XX% fiscal as year-over-year adjusted to pricing and our global and volume opportunities volume as see Crescendo transformational margins forward basis and tests. with XXXX And substantial and personalized additional in with medicine quarter. led we improvement we year-over-year towards so company. our reimbursement we year diversified of strides total Myriad to volume double digit growing the fiscal in significant key X% despite a from a year-over-year, was pipeline in Moreover, declining continue million attributable quarter products to year the progress significant progress a for advancing This down XXX adjusted We Elevate a fourth foundation Finally, growth. international

Finally, leading to we growth. profitability increased the efficiency of our XXXX organization through significant Elevate programs, our

believe completion the we of Bryan As call results accelerate. and will guidance. transformation fiscal With turn financial the our of the I Counsyl the the will we look recent that, to acquisition, to to over to discuss business with continue XXXX,

Bryan Riggsbee

the with by our to results. new and like financial quarter being we million would $XXX.X fiscal the hereditary revenues year-over-year in product $XXX.X to declines start cancer I were hereditary total fourth Mark. of Fourth year, reported period of X%, same in providing compared volume in-depth million in a overview cancer Thanks, up by quarter pricing the more offset prior growth.

X% XX% year-over-year basis three million, growth. revenue Notably, and sequential cancer with for sixth at pricing been continued and pricing up once again, in quarter, consecutive for excess and run GeneSight year. new anticipate in we a has fiscal again quarters year $XXX.X the in ended in was throughout of the stable grew the XXXX. per revenue Once volumes on a volume X% exceeded we increased stable year and the record sequentially quarter million a rate tests was growth consecutive quarter the volume year-over-year. well and Hereditary quarter XXX,XXX $XX.X achieved

fourth volume in EndoPredict revenues fourth $X.X reimbursement increasing U.S. relative doctors to of of largely XX% to Mark interests earlier in the quarter XXX% following attributable the new set was the the new this As record by the and to was the patients coverage ordering GUIDED and in of physicians the record for double-digit primarily was We which Psychiatric year-over-year. growth. a ordering and mentioned quarter also million in Growth call, the year-over-year. reflective physicians ordering the EndoPredict are presentation the expansion in favorable American on physicians, study growth. in Polaris XXXX. record the Meeting. incremental Growth growing hills adoption quarter leading at set from at strong record total was fiscal recent in quarter quarter, DA at the up Association fourth revenue strong revenue XX% and was these the million quarter $XX.X a fiscal Vector in intermediate million Medicare future indicators and new trends fourth $X was grew revenue Annual driven believe in of the markets. the

in The incremental These process associated revenue were last new saw DNA, metrics we attributable this announced we year-over-year. strength financial and clinical margins for at XX.X%. of partners. continued to services and of strength the call. our become the pronounced improvement RNA are grew in activity to quarter RBM more from that our would clinical on gross gross will XXXX. I partial programs year for the and they Adjusted discuss product and pharmaceutical our as again, quarter. business reimbursement Myriad with our, we was margin efficiency with pharmaceutical Once robust trial $XX.X like million laboratories Lastly, protein was implementation our saw fiscal fully-implemented X% new division

$X.X GeneSight fourth operating Moving quarter to expenses, a approximately of million $X last expenses our to $XXX.X declined decline was attributable our compared compared $X.XX fiscal XX%. cost initiatives. quarter million, to the year year-over-year, our adjusted $XXX.X This completion an expense expense million double-digit quarter, volume of the and $XX.X to last year. on almost XXXX Elevate XXXX. SG&A in of share Adjusted per on research test basis, for million, development study. and an the The growth. the to earnings of was research of million result sold were including year the Adjusted entirely largely fourth compared increase reduction fourth in $XX.X GUIDED Total this of development expenses $X.XX in million was goods despite quarter

count increased million Our shares outstanding. fully to diluted share XX.X sequentially

-- generated is repayment a as two We use in facility. this We on ended $X the repaid be cash. years to our cash the near-term company. million continue It million debt of less to by will with prioritize of note quarter outstanding remaining Assurex interesting $XXX that on credit with than our acquisition the

quarter. million, equivalent at to cash end fourth balance and was compared at million $XXX which the cash of $XXX the end the of third Our the quarter

fiscal than was per understated in per significantly We cash cash quarter share. EPS our continue to in significantly fact, Historically, our share, per flow or which generate $X.XX higher share, the free adjusted with free approximately meaningful have free adjusted flow our and adjusted our per XXXX. year of per XXXX, $XX.X million cash compensation order earnings to flow share to we In flow from earnings more earnings of the and share in accurately the our per $X.XX cash consistent with other business starting for represent decided stock-based free adjusted exclude our was fiscal growth technology have expense companies, power share.

the or expect stock-based share. fiscal expense in compensation approximately $XX XXXX represent We per $X.XX year million will

like our XXXX team revenue that identified during the our fiscal year were Next, to financial I would adjustments close. by discuss finance

analysis the adjustments flow through fiscal aggregate, bottom adjustment over a to adjustments hindsight, reported identified the our XXXX. of quarter third reported to our year line to these total perfect there XX/XX the the financial a that XXXX for of nonmaterial net revenue In period. earnings. represent tax, corresponding the fiscal with our XXX period from adjustments X.X% these of XXX for team is transition completed we revenue results ASC As to benefit directly ASC from and Because

a had be adjustment to for the deemed future for reporting. accounting will be procedures include hindsight’s by adjustments and These Young auditor were and quarter all our financial not Ernst material in understated. slightly our basis adjustments revenue While provision & was approved been every for made process

For $X share and aggregate fiscal associated was to the $X.XX. with findings earnings the year XXXX, total impact these revenue was impact adjust per million

XXXX fiscal For million adjust revenue year the impact was to $X.X earnings share. was and impact per to share the per $X.XX

financial Now guidance. I discuss would XXXX year our like fiscal to

to guidance. now revenues $XXX the XXXX, relevant to $X.XX. million to year guiding million and fiscal earnings of financial For adjusted of discuss I we per are of this will drivers share $XXX $X.XX

guidance million financial is of by $XXX from reduced XXX. revenue the million, $XXX our ASC perspective, First, which organic of assumes a revenue to impact

this our in beyond no Secondly, in of sale the additional no know our fiscal of the in X%. XXX assumes of reimbursement to already adjusting be year the place six corresponds what German for of and financial the revenue the fiscal revenue, revenue growth guidance After of ASC with second first X% half guidance for revenue the organic fiscal clinic clinic assumes the we half Also, months guidance year. to year. to

we owning upon rate assuming fiscal million run months year approximately in current revenue with the XXXX. based asset Counsyl, For of XX in $XXX are

that fewer double-digit due pharmaceutical guidance assumes XX%. product offset in This some are in sales assumption contracts. a a every revenue no revenue force services and of guiding pharmaceutical growth assumes growth integration from be revenue research we and implies decline and new XX% known synergies will increase revenue disruption nominal of cancer to revenue for Our reimbursement. hereditary by our Counsyl revenue guidance Overall, to to

known XX% a assumes will stock-based be impact be neutral XX year shares. that to and XXXX XX% a fiscal program from the earnings, and excluded share assumes to Counsyl approximately fully earnings will compensation diluted Our XXXX count of that corresponds million increase guidance Elevate acquisition to additional

financials Additionally, consistent a our rate commentary, of expect approximately prior tax our adjusted XX%. with we on

the upside would fiscal drivers year XXXX. discuss our I to potential like to Now guidance for financial

our of see the GeneSight, GUIDED, are Although, to assumes guidance for IMPACT Optum we increased believe known coverage studies. strongly positioned publication only we following the and reimbursement,

As a line. vast -- drop the coverage noted, represent lives the revenue, bottom representing payers an commercial in in would commercial additional alone Obtaining reminder, as addition, payers the XX% decisions we these will already which have million we of with contracts $XX majority country. to of

to would reimbursed Additionally, if LCD another market or the study, include the increase care it million. addressable by based the X% IMPACT GeneSight upon Medicare expands physicians primary $XXX

Our primary not the GeneSight XXXX. guidance assumes that will into we fiscal launch channel care in

However, reimbursement, will sales we into with our targets care. sufficient expand primary

As a assumes also reminder, Vectra or of Melanoma. half primary Prolaris, for for represents care no market Guidance the additional than GeneSight. EndoPredict, DA, reimbursement more myPath

a standard-of-care likely as supporting of we XXXX. the For Clinical is recent Physician positive updated Medicaid and significant We lower from coverage will and seen it a decisions and in risk in paper insurers based -- NCCN state decisions favorable year fiscal commercial women. guidelines biomarker believe and American Prolaris, testing have Association upon we the low number additional of intermediate reimbursement Urology see

anticipate recent We are DA fiscal Vectra discussions by stage see decisions, Melanoma, MolDX employer the professional coverage guidelines, the decisions coverage the program we anticipated Vectra we test year. of favorable. and incorporate guidelines into and and which provisional of employer obtained NCCN commercial that could payers in Rheumatology being with are note Kroger this believe College updated regional with we have the DA, if with late coverage eight agreement and could year. guidelines their Also calendar For commercial myPath Medicare the additional considered the American end test for believe the is are

myPath test have these we possible this no will revenue While is in XXXX. guidance, given developments, year it generate included revenue fiscal and Melanoma that

sales materialize, size also dermatology expand reimbursement we team. decisions to look of As the will our

noted, as past indications the have year. in cancer than totaling substantial six we addition, per months for expansion more additional In hereditary patients seen in testing XXX,XXX

We already penetration although and been have initiated. these to have marketing significant not assumed sales markets, any efforts

Counsyl on acquisition. to the Moving

upside the guidance our to associated occur, previously would our guidance. with integration. does represent I revenue force sales of stated, it this extent the some As assumes level To disruption not

associated with the code. Additionally, we increase carrier expanded no assuming foresight new are in screening reimbursement

any in for Medicaid not from coverage patients coverage states. or from including also are -- We assuming insurers commercial average incremental additional coverage Prelude covering for risk

XXXX despite it if assumes in these to synergies, be test one guidance only our calling these additional additional of would $XX no each an the that in order Lastly, accounts revenue will OB/GYNs. month, The per million were on and we physicians represent business is potential an fact substantial revenue.

leading are to quarter, financial includes for million company. believe personalized our fiscal first will revenue, Mark bottomline guidance year into on two of could top we can we From year and of substantial able to a drive significant flat approximately upside there and Moving diversification expenses generate negative discuss business fiscal which perspective, financial inflection and includes exceed turn months we the substantial XXXX. will incorporated from million quarter EPS assumes significant material to the I I profitability We fourth see, current number all we comparative fiscal of on medicine build you a Even earnings in to the $X.XX momentum approximately From $X.XX our perspective, are million. call the revenue growth and cusp guidance our the $XXX With $X.XX. as results. onto our world’s to significant Counsyl to the would am to Counsyl guidance business adjusted to that, revenue seek XXXX to reimbursement, of the with and catalyst, highlights. Reflecting revenues total XXXX, and we tests ASC the clearly From impact be the of of XXX our guiding of sequential been were carry now fiscal XXX. as an and pleased over assumes are the typical have summer revenue $XXX per a $XXX from if ASC relatively perspective, acquisition share. dilution impact into assumes

Mark Capone

nominal grounds assumes XXXX. current do our an rates from cancer we inflection Yet perspective in to excited details our execution discuss our am I in growth growth business cancer a relatively see volumes. to new guidance Bryan. in create opportunities important fiscal more hereditary Thanks, hereditary around

than in increased patients First, fiscal pancreatic pancreatic or that guidelines with were changes XXX,XXX by cancer XX,XXX National year. given in XXXX. cancer patients fiscal will history patients eligibility year more in patients for additional per the changes made XXXX, meet Comprehensive criteria Network per of a Cancer family Significant unaffected

Additionally, NCCN recently per colorectal incremental its will high broadened guidelines on that an for to eligibility colon patients risk lead cancer year. XX,XXX cancer syndromes

in prostate to hereditary July, XX,XXX its Finally, patients NCCN metastatic of cancer testing per history guidelines all family and patients cancer by include breast updated increase all patients eligibility the with which year. cancer,

of opportunity in data deeper including continued clinical riskScore will women’s enhancements rates Another extensive to further additional we ethnic the for the year launch riskScore test with riskScore. health leveraging penetration XXXX double-digit validation market driving saw in growth XXXX be patients represent new growth histories to ability of an market. fiscal further to expansions with will data fiscal less power relevant predictive of inclusion enhance populations. into groups, impact expand the and We additional the XX% family of the the into into broader This already by that

to companion opportunities growth. diagnostic Lastly, new from a we perspective, continue for see

December filed the will Pfizer applications have in Myriad date fiscal same with the already have increase sequential the launch efforts as Lynparza cancer breast of XXXX. talazoparib metastatic XX% in volumes quarter. for third PDUFA with the fiscal in We FDA and growth seen Marketing following this year indication

cancer this ramping have metastatic samples addition U.S. June up. CDx Japanese opportunity, received seen already we breast approval and to in for In BRACAnalysis

XX,XXX As a opportunity reminder, Japan about the patients per in year. represents

supplementary advanced plan submit we for SOLO-X ovarian with AstraZeneca trial. PMA Additionally, BRACAnalysis to first CDx the cancer, line in a outcome consistent of

less is XX%. testing than market into ovarian cancer Our of penetration the still

With higher a with study GeneSight, X,XXX the encouraged of unblinded publication received IMPACT So Optum primary an the and study IMPACT treated were all an of psychiatrists. was better with of outcomes study care a patients improve reports. which the are The treated by patients by were comparison of patients were remission the These IMPACT with The publication to significant. physicians and XX% was improvement, higher endpoint physician symptom future In earlier GeneSight patients and test the outcomes care results physicians. rates part primary prospective primary compliance XX% response indication and of the the actually adoption. fact may care we GUIDED of study. that in primary results all higher higher the rates XX% study, there rates, with achieved to attributed statistically

study this from will is be the important observation of data the IMPACT the Because the Another and is strikingly outcomes primary before outcomes for in similar asked GeneSight supportive we expanding of GUIDED are LCD, the study study. the that care their specifically for publication the arm in Medicare submitting consideration.

review The the critical catalyst the other XXXX. expanded in publication to publications decisions we Having of two latter these met coverage GUIDED key the fiscal stages will are all process. Optum be throughout on country, the the latter papers study on in the and study are the with study believe the of top players

is employers. One on of strategies directly coverage our reimbursement working self-funded decisions new with

quarter major in covering GeneSight. interest saw we two national employer express This groups

improved employer of employers these negotiations employees. from major We see the XX,XXX with Because in late-stage the productivity, upon these their United and States groups in decisions. apparent. provide personalized assess payers the as even benefits Approximately GeneSight helps also products, are commercial employer demonstrate we another to the lives cost of to impetus signed savings coverage are United nationwide with of collaborations self-insured increasingly employers and for covered for high employers. interest level by coverage States, XX% largest We medicine are and in fourth it Kroger, approximately the employer more the insist the believe both self-insured the

Myriad to starting Counsyl and representatives we Moving ForeSight tests. on train acquisition, to the the the Prelude are

have amortize and noninvasive included determined with a our represent team have portfolio country. this these currently prenatal we accessed the about not It Myriad in overlap only market sales been half to but by Counsyl’s the territories, is for in potential of of we substantial targeted by doctors incremental Counsyl. our sales the guidance. sales screening OB/GYNs are we evaluate have we OB/GYNs that tests, expansion. call territory the As We for broader believe are also there screening not carrier note tests still that to the a on With expense, evaluating force important X,XXX

private million multiple coverage. saw believe Prolaris, see the low with Urology which in standard-of-care testing XX technical payers inflection with paper, complete now we process including fiscal Clinical Throughout eight commercial in additional as position and biomarker determinations reimbursement new is have we and For We favorable risk coverage following five prognostic and will national American recognized a will an payers NCCN top the intermediate prostate Association comprising we cancer. expanded payer. guidelines lives XXXX, covered likely assessment it of

this However, expectation reflected we have our guidance. in not

on pleased we myPath now I to covering announce have test. payers eight Finally, Melanoma, the am that

also are LCD draft for on believe and its test inclusion discussions late-stage NCCN considering professional the guidelines. with We Medicare is a in

despite not year positive Melanoma. developments, I Overall, prospects does pleased XXXX I year with any fiscal company from our a in our our However, excited for these include XXXX about am guidance fiscal progress exceptionally fiscal revenue as XXXX. and myPath am

remains volumes in cancer a solid hereditary with foundation We a market stable less XX% than pricing penetrated. still and growing have that

reimbursement of markets on robust product In a believe and at highly addition, double-digit significant are we in volume coverage. the we continue to a expansion pace underpenetrated cusp grow new in

our the back our material delivering patients path strategic reengineered to committed pleased for Q&A. with projects our additional we goals am Elevate talented and With I passionately Lastly, for clear multiple Scott have achieving turn shareholders. team call and results and over our to The impact XXXX. is our cost have XXXX to is set that, structure fiscal to to

Scott Gleason

Mark. Thanks,

the reconciliation As be guidance a GAAP measures. non-GAAP can non-GAAP financial section found to GAAP Investor website. financial today’s non-GAAP use financial reminder, our to under certain the A reconciliation of results and call, we Relations of results of during financial

ready are participants begin order one our ask ready to Q&A Operator, now participant broad In only of Q&A session. Q&A we in follow-up. we Now, session, today’s the and are for portion one please call. to ensure we the ask question to

Operator

first line moment Thank Murphy the question, you. go Blair. Amanda One which the for Please [Operator William Instructions] of please ahead. with from comes

Amanda Murphy

Thanks. Hi.

is conversations so the with the over was making of thus the have payers, to a there I what companies some you assay? diagnostic of generally so tests been here maybe CareFirst, at idea are if this also data the where on as if so is building the free would in bunch point of the I And speak, just gotten thing, So, terms of the question got of why just you this projections curious then they up kind I point just of endpoints. in obviously, line, just for had throwing some conversations around am being space they we just like lot get kind a more if so almost it kind stand your the at are you GeneSight, just there? curious some just this cover as that am the doing in then testing could and what so of also already far. a you curious with payers kind to in data of cover of kind idea payers kind perspective done feel them And community, of got from reimbursement. the have with And investor obviously, just various progress have

Mark Capone

I these I to of I miss hope all if something… Amanda. Thanks, get

Amanda Murphy

Sorry.

Mark Capone

… please will cover follow rest, the okay. up, I okay.

First, to with had perspective interact actually chance their I to and a I see CareFirst personally response. them think, a get and from

very evidence. that thing impresses all, response To They that the the with most a second it rates for question, starts payers couple really First your reasons. clinical is with in the of the evidence. were impressed reflect remission on clinical

cost what look at is resistant year. The a you patient that it’s first $XX,XXX per treat about data patient that’s treatment if remission well that to depressed in known it

that can you to year. patient respond $XX,XXX you into save if patient get save that year, you you $XX,XXX a a remission, If get

money. to that remission the payers and going that matter, ones the as response ones ones drive those the really and the so in guidelines physicians, that are exception have value because without focused to on are ultimately for endpoints those are value drive And for patient, them save those are are the that those that endpoints

It’s impressed were compare drug with had in studies seen really when they It’s data an you that, prospective been produced like never arm. so, just active particularly And very before. this. never to they

think and have response. on all been focus that board -- payers we really continue and across talked I remission as to the consistent to that’s

that that when star that response to are endpoints note they ratings. it is are the to thing and other remission The generate they HEDA looking higher try at as two is scores matter

plays to it again, so, and they what into a exactly are perspective perspective. from looking clinical And economic a health

cover we in prescribe that physicians primary country. half standpoint a that as the marketing to why the of not this from over this, antidepressants Now, of currently mentioned, we are care care recognized primary setting,

something reimbursement see we and to need you have once do financial the do if care justify fact that’s to the that primary you really only going sufficient benefit in patient so, benefits setting that that. in are will we the and both to And

don’t Secondarily, opportunity all which the and psychiatry a psychiatry the we with so, health just call this our will into even psychiatrists, advantage point. psychiatry much again, market on payer. the portion there further reimbursement, in to as the market only again tell reach an and of XX,XXX patients for a increase We at well call is of expand point, economic

a stop there you have see if Amanda. me let follow So, up,

Amanda Murphy

Yeah. look, and have so you anyway. and sort the say, curious I about others you volume I back levels point I -- obviously, of companies have, have the to doing Myriad a where space But, have, and am basically asking I think, tests three that what push the test a and guess, cover I And around in I are you won’t so question. regardless just guess, at like it since one question keep broader payers that been asked been are to level higher have at tests reluctant you was long talked for performing. going guess, I I we was do

actually still curious versus patients? and there coverage So, for test performing just give the the take with

Mark Capone

are is I of market think broad of do is to that to that of that’s look are we now going really benefit right That’s only is large their that something their not Yeah. reimbursement. at get to chance Again, and want swaths psychiatrists and to care. primary into the ways perspective there which market getting focus. all Was a GeneSight, the get this majority of additional they once we a have the

we perspective today. get much can if and of than set is broader to we work their a that patients this together them there benefit to much, currently So a do is

Amanda Murphy

Got it.

so Okay. much. Thanks

Operator

Jones question Stephens. with next The go ahead. from comes of Please the Drew line

Drew Jones

guys. Thanks. afternoon, Good

Mark Capone

afternoon, Good Drew.

Drew Jones

just any -- on lines, kind there? of going following give GeneSight, an could you you us maybe could maybe RCT on on publication, insight up Mark, update time on our what’s

Mark Capone

Yeah. Thanks, Drew.

I in study. actual the now of As the the is GUIDED remarks, got is official prepared which RCT noted name the

had for the that. had in at this publication we we that fiscal of are of stages accelerated would review initially beginning latter year. Obviously, more hoped We review with get the

of review. hasn’t in summer I particularly think large what accelerated really that the a we have number typical authors it review process months seen and is with been

more as I on work by are obviously continue quickly But authors review at the a it. has with point. think we line publication publication, we so this we typical this a through time of complexity But with this can. to be rounds traditional process we and as multiple response encouraged

that can. published But, we encouraged and line right as what getting I are focused seeing are think, we as now. again, we a time typical on this So, soon is

Drew Jones

growth once look met the ‘XX came quarter in, half visibility the And me. of is contribution trajectory, that in breast especially third better terms that that later to of is year from back one far you how as Do how Okay. any CDx fiscal the last in see have if progressed? trajectory in you and maybe then and on guys can

Mark Capone

breast of the middle the quarter. came the met really for Well, the third indication approvals in

think, is cancer. I increase prepared that really to we QX in data point that get the we first provided the QX from that patients I metastatic with remarks could read sequential in saw XX% on So, the breast

those So nice in for we obviously patients. uptake increase saw a

got ‘XX, to just we mentioned, from we as there the only other And we are in where I a That of approved here couple think as samples product we turn came have the contributors BRACAnalysis quarter. Japan online the ramp page a growth. Japan. in CDx. have here to obviously up with already first fiscal I seen

opportunity. that’s So another going to be

see are salespeople We the so cancer metastatic importance effort doubling a indication in for in now a patients. also cancer and Pfizer substantial that companion of our will is testing will talazoparib diagnostic breast you the metastatic will as of gets marketing talking there and the number in doing and date about be in December breast approval increase the for out be PDUFA there BRACAnalysis same

as we in from QX to saw but manufacturer QX, a the just of as bring Japan, bring another nice of the in year. really middle are on early that I we we So growth stages pharmaceutical think we the on

Drew Jones

guys. Thanks,

Operator

go comes of question ahead. de from next of line The Please with Bruin America. the Derik Bank

Unidentified Analyst

Hey. Derik This Bruin. on [ph] for Amy is de

Counsyl. on Just question a

other are it bit detection for some there acquired et rate, ForeSight and by situation more? services, the differences a just a offering can cetera mentioned the and good So, you. investment carrier you [inaudible] what many update was I little between screening on and companies are higher competitive Thank to wanted which maybe product. the see vendors part us

Mark Capone

for question. of Yeah. Thank don’t know caught if -- every the I I you that. all

was question a see choppy. Your of some the think line ForeSight do I really But was advantages. the we as little around what and

Counsyl in our and we a course, ability that ForeSight that of workflow includes be this we things of integrate their will is adding Prelude, process the into and now, very attracted smooth to very to of test. One cancer were all hereditary and

of few owned they a complete they those an smooth that, health, office we clear want important very a with exactly solution they is, that the opportunity So tests the now for can quality the is, like heard just in tests. have would Myriad an that have and going test and women’s the weeks workflow that launch asset just are a for we they already integration the best highest with that of to OB/GYN single have in how

ForeSight, deliver see Counsyl to with have results was they might pioneer got and the the and laboratories. have some accurate so and carrier ability advantages as they than other more pioneer test in patients results their and fact screening clearly in expanded advantages to the

it’s reach really for can think, quality. it’s the we if health and I that much that organization expanded integrated Myriad that ability workflow, reputation women’s for an now So, broader provide as that

in are others us market. going that those things show I be for advantages to of opportunities to the think relative all to are

Unidentified Analyst

in I just you. one Thank more housekeeping. If could squeeze

see it’s you life that? to why company rationale sciences Thank common exclude decide what other Stockholm, the your not with to FYXX? this, what’s or the So From suddenly understand behind from $X.XX wanted did exclude practice to just you. I diagnostics

Bryan Riggsbee

Yeah. Thanks for Thanks. Yeah. the question.

we peers we we based it industry free adjusted by to the they the it. information cash think Also are more relative a better cash business course around is ultimate exclude that’s the of earnings share, that that provided per as through and business. providing share on I relatively our look flow our are look is really investors to more and the excluding understated on on had focused the felt we what generation get in free the questions it of dramatically power the that common flow and at and have per of the started year I which think earnings of last measure we

So that was really the that. thinking behind

Unidentified Analyst

Okay. Thank you.

Operator

ahead. line Sung from the comes BTIG. with go question of Please Nam Next Ji

Sung Ji Nam

could self-funded self-funded I taking market. -- probe into Mark, wondering the for I questions. Thanks the employee Hi. market was if further

with in is self-funded that the Sounds employee of And where there sets you criteria of publication terms kind are like for after study parties? commercial to it’s need the terms And of address example, obviously GUIDED payers? price you that significant important you in would of going you there, for different market? both for the a the of as hurdles do it the important equally see hurdles, think see as the if, do for as opportunity

Mark Capone

Yeah. you, Thank Sung Ji.

about have -- really for is for perspective portion we most matters ultimately example, and and and is of good a payer the We we anyway these just us made that. health progress are funds self-funded care given pay from all of what well. the administrative and a employee wellness we excited in already productivity is And as are Myriad a that

for best health our control to And in and comes employees when the so what’s our best seat what’s costs. we are care decision-making to it

a of things. of and capture So on they those they payer the improvements types productivity don’t lens whereby that’s part excited have we are reason from a perspective, because complete this

we reception. very in something is This XXXX. just started So warm a have we had

stages. So, in the we early are I think

level begin as Parkinson significant the his think how the have how year see of the And country. will actually in rest to opportunity is focus I and we together to plays fact out to try to very see that. and Chip to on been more big this has find endurance joining from in think, you actually challenges significant, employer I now team different the groups efforts our significant. healthcare But solutions

are we that so playing into dynamic. And

from it think would. as like approach, literature, They are that they medical I very generally societies. the rely on they another but guidance tech have payer documents hurdles use at may professional out of perspective, not things for look they much extensive assessment a there

that’s between employees some we for so the with still are been is can similar very and and very a are self-funded for view get our things they consistent say discussions that. those looking well to similarities those remission a theme trying there matter for that GeneSight So on our I example response, to looking are payers employers. their that in is and again, are commercial and because they

Sung Ji Nam

impact helpful. attributable the very XXX product revenues for or That’s just that hereditary largely for And just that adjustment other ASC -- you lines, for especially for a that -- is is cancer one Okay. to purposes. provided, quick Bryan, curious modeling

Bryan Riggsbee

lines a would ASC hereditary, I on Yeah. model attributable XXX. Sure. it’s was say were business that the already largely other consistent with relatively

Sung Ji Nam

Thank Great. Okay. you.

Operator

Barclays. Please of line Jack the go The ahead. next comes from question Meehan with

Jack Meehan

Hi. had is us conversations for have them market? primary wondering the on CMS-related could and Good any you potential and care GUIDED related the Mark, with you studies GeneSight update some an afternoon, and timeline give I to IMPACT from think color what the if you everyone. was

Mark Capone

care very on and coverage see Yeah. for CMS to how compared to psychiatry-only that tool using physicians would back was even well like It we provided Jack. the Thanks, market the that early then actually this psychiatrists. primary was obviously feedback do

probably did report. of is obviously that the even surprise They study following genesis to test IMPACT And question And data the because the were so more diligent was the specifically better. probably they that’s at from not it’s a the CMS, outstanding. from entire answer really results

and be that for doing. So will publication approach were with that’s waiting we, obviously, we that Medicare to what

Medicare but the and are interested results so They they expansion go GUIDED discuss publications the the those seen to with with all study with topline is as care because have those plan the potential into to impressed approach very to they primary then well, were LCD that want the with of Our GUIDED. we of of results and both publication on forward market.

approaching happens, with will them be immediately both can you that GUIDED that we of publication after as these. So assume

to of think data excited answers talk to this all it. So, to and questions get them about we their

Jack Meehan

for the Thanks Great. color.

follow-up, the be XXXX the can is Thank as me could within or any the related was helpful? and Just that you with hereditary would XXXX to what decline I grow help a assumption contribution in hoping you. guidance environment pricing from on thoughts cancer

Bryan Riggsbee

Yeah. Bryan. Yeah. this is Jack,

think that consecutive have comments seen quarters we have stable of as made I the pricing. three are few one we

But we the locked through say got pricing FYXX. we get in. hereditary But We expect relatively new that that and year year I will that to year fact will products. the nominally continue stable through just again double-digit a that would by I for -- would our have increased increases and offset next the think, assumption lower next hereditary cancer through stable also some given then be be relative to cancer, contributor would the RBM revenue be

Jack Meehan

Bryan. Very helpful. Thanks,

Bryan Riggsbee

Yeah.

Operator

Sachs. comes question Patrick of Goldman Please Donnelly ahead. line last from the with go The

Patrick Donnelly

and Counsyl through you this of clarification upside, a on just what synergies, guidance. assumptions quick assumptions it baking talk through in the to curious year. baked for it like just only Great. Counsyl, you any leaving ‘XX. know just in another seem get there, the kind just XX are on Thanks, doesn’t most talk you Maybe year months am in we of Can growth what’s in I it are revenue guys. I a lot but the of Can

Bryan Riggsbee

relative we we in at I just going Patrick, disruption the revenue guide. terms synergies an Counsyl million to upside we for it any time but the revenue that year, the months, next our commentary terms occurs, asset that like have obviously, of we out there acquisition XX Yeah. own are to is those around left $XXX you expect if guess, to have is in had of that do for number that be some

Mark Capone

disruption, So, of part way offset by current in some very of Patrick, expect opportunities growth Bryan mentioned. the we as rate be a basically that to run simplistic just and is because assume we

assumed run we just So rate year. next for fiscal have

this Now, which that, a at different our probably point. only is that you this have the assumption can much few But of than particularly a building guidance obviously, on prudent so something penetrate not for that’s we on point. asset any all, had imagine the that is weeks opportunity but the X,XXX at haven’t we focus in called at with OB/GYNs to

Patrick Donnelly

Okay. is in rev relation And that cannibalized kind have just kind kind that X% to the hereditary trying going they disruption was like to revenue is of seemed potentially a around there? of of way, I be the that to tied figure a primarily am that but it cancer, out,

Mark Capone

you so with teams and as hereditary it’s market look together exactly myRisk we with sales bring those are not hereditary product integrate doing their that myRisk us No. of it right the there merging and are sort to the of -- Obviously are to now. some assess But do product. begin related we historically, assessing when leaders have volume It’s an to disruption It’s two just It’s not teams. result sales time that. gives is opportunity volume opportunity you obviously, just shift cancer. an the we to the you that cancer two into is to where and more going what territories, any just typically

is be typically you the So look are those together at just immediately and we sales on forces allocate But disruption. that happen. try we the make working to two things territories that is that bring those, there mentioned disruption will to as really some

Patrick Donnelly

through the still there quick then dilution weeks talk may know what curtains Counsyl for neutral of synergy more have XXXX kind opportunity, of you XQ, only the expecting few to I you just few just to and seen expectations maybe be have in but give on cost a number EPS first can one been side, for And behind here. here? again, Okay. you just But the the kind one and the you weeks

Bryan Riggsbee

Yeah. Sure.

I is relative think asset. early right. It to days the you owning are

hard accomplished has in few few it’s have anything to quarter, quarter. I the and points would days. really the or to That really get data XX the yeah, think One, the impact the have would an impact relative I comments to be. first first an

the are ramped it year, I think neutral up. the be projects very fact to still So going a that little take earnings for to of with we but bit us will comfortable it’s get time

to think executed. this compare the think I going and get to but obviously acquisition. channel Assurex, about just you that with little for the didn’t we here to to that time and opportunity, we relative We that opportunity respect bit have contrast synergies, overlap believe a to fact there significant take as relative is that it’s of have

Patrick Donnelly

Okay. you. Thank

Operator

closing the There are call time. to now your and turn presentation Please the remarks. further back this will you. questions no at continue I

Scott Gleason

via for will this call. Thank again A you on webcast you. for available our Thank replay week. be This website concludes joining our one afternoon. us earnings

Operator

that for the you ask that participation your does Ladies line. and and We today. disconnect please for thank conference call conclude gentlemen, you

Myriad Genetics (MYGN) 21 Aug 182018 Q4 Earnings call transcript